salvianolic acid C: mTOR inhibitor from Salvia miltiorrhiza [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Salvia | genus | A genus in the mint family (LAMIACEAE).[MeSH] | Lamiaceae | The mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH] |
| Salvia miltiorrhiza | species | A plant species which is known as an Oriental traditional medicinal plant.[MeSH] | Lamiaceae | The mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 13991590 |
| CHEMBL ID | 4077922 |
| CHEBI ID | 140104 |
| SCHEMBL ID | 19236216 |
| MeSH ID | M000605711 |
| Synonym |
|---|
| salvianolic acid c |
| CHEBI:140104 |
| 115841-09-3 |
| i16h9z53zl , |
| unii-i16h9z53zl |
| benzenepropanoic acid, alpha-(((2e)-3-(2-(3,4-dihydroxyphenyl)-7-hydroxy-4-benzofuranyl)-1-oxo-2-propen-1-yl)oxy)-3,4-dihydroxy-, (alphar)- |
| (2r)-3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-benzofuran-4-yl]prop-2-enoyl]oxy-propanoic acid |
| AC-34154 |
| salvianolic-acid-c |
| benzenepropanoic acid, .alpha.-(((2e)-3-(2-(3,4-dihydroxyphenyl)-7-hydroxy-4-benzofuranyl)-1-oxo-2-propen-1-yl)oxy)-3,4-dihydroxy-, (.alpha.r)- |
| AKOS026674262 |
| mfcd16660675 |
| (r,e)-3-(3,4-dihydroxyphenyl)-2-((3-(2-(3,4-dihydroxyphenyl)-7-hydroxybenzofuran-4-yl)acryloyl)oxy)propanoic acid |
| SCHEMBL19236216 |
| salvianolicacid c |
| CS-0008886 |
| HY-N0319 |
| (2r)-3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-1-benzofuran-4-yl]prop-2-enoyl]oxypropanoic acid |
| bdbm50233805 |
| benzenepropanoic acid, alpha-[[(2e)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-4-benzofuranyl]-1-oxo-2-propen-1-yl]oxy]-3,4-dihydroxy-, (alphar)- |
| CHEMBL4077922 , |
| Q27280236 |
| BS-50422 |
| (r,e)-3-(3,4-dihydroxyphenyl)-2-((3-(2-(3,4-dihydroxyphenyl)-7-hydroxybenzofuran-4-yl)acryloyl)oxy)propanoicacid |
| DTXSID101341785 |
Salvinolic acid C (SAC) is a polyphenol compound with anti-inflammatory and antioxidant activities. It is isolated from Danshen, a traditional Chinese medicine made from the roots of Salvia miltiorrhiza Bunge.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Salvianolic acid C (SAC) is a natural compound derived from " | ( Salvianolic Acid C Inhibits the Epithelial-Mesenchymal Transition and Ameliorates Renal Tubulointerstitial Fibrosis. Chen, D; Huang, D; Lin, J; Wu, M; Ye, C, 2023) | 3.8 |
| "Salvianolic acid C (SAC) is a polyphenol compound with anti-inflammatory and antioxidant activities that is isolated from Danshen, a traditional Chinese medicine made from the roots of Salvia miltiorrhiza Bunge." | ( Salvianolic Acid C Attenuates LPS-Induced Inflammation and Apoptosis in Human Periodontal Ligament Stem Cells via Toll-Like Receptors 4 (TLR4)/Nuclear Factor kappa B (NF-κB) Pathway. An, W; Duan, Y; Wu, H; Wu, Y, 2019) | 2.68 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The validated method was successfully applied to pharmacokinetic study after oral and intravenous administration of salvianolic acid C to rats." | ( Determination of salvianolic acid C in rat plasma using liquid chromatography-mass spectrometry and its application to pharmacokinetic study. Du, G; Feng, Z; Song, J; Sun, J; Xu, X; Zhang, L; Zhang, W; Zhang, X, 2016) | 0.98 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "In this study, capillary electrophoresis (CE) combined with HPLC-MS/MS were used as a powerful platform for screening of inhibitors of mammalian target of rapamycin (mTOR) in natural product extracts." | ( Screening of mammalian target of rapamycin inhibitors in natural product extracts by capillary electrophoresis in combination with high performance liquid chromatography-tandem mass spectrometry. Kang, J; Li, F; Li, M; Zhang, Y, 2015) | 0.42 |
| Class | Description |
|---|---|
| benzofurans | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Xanthine dehydrogenase/oxidase | Homo sapiens (human) | IC50 (µMol) | 8.2600 | 0.0013 | 2.8138 | 9.8200 | AID1433308 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | IC50 (µMol) | 3.8500 | 0.0300 | 2.7731 | 9.5100 | AID1753195 |
| P2Y purinoceptor 12 | Homo sapiens (human) | Ki | 15.6000 | 0.0020 | 2.8220 | 9.8300 | AID1871462 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytosol | Xanthine dehydrogenase/oxidase | Homo sapiens (human) |
| extracellular space | Xanthine dehydrogenase/oxidase | Homo sapiens (human) |
| peroxisome | Xanthine dehydrogenase/oxidase | Homo sapiens (human) |
| cytosol | Xanthine dehydrogenase/oxidase | Homo sapiens (human) |
| sarcoplasmic reticulum | Xanthine dehydrogenase/oxidase | Homo sapiens (human) |
| extracellular space | Xanthine dehydrogenase/oxidase | Homo sapiens (human) |
| virion membrane | Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus |
| plasma membrane | P2Y purinoceptor 12 | Homo sapiens (human) |
| cell surface | P2Y purinoceptor 12 | Homo sapiens (human) |
| membrane | P2Y purinoceptor 12 | Homo sapiens (human) |
| cell projection membrane | P2Y purinoceptor 12 | Homo sapiens (human) |
| cell body membrane | P2Y purinoceptor 12 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1424740 | Hypouricemic effect in iv dosed ICR mouse model of potassium oxonate-induced acute hyperuricemia assessed as reduction in serum uric acids level measured after 1 hr post dose | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Design, synthesis and biological evaluation of novel xanthine oxidase inhibitors bearing a 2-arylbenzo[b]furan scaffold. |
| AID1859992 | Antiviral activity against pseudovirus SARS-CoV-2 spike protein infected human HEK293T cells overexpressing ACE2 assessed as inhibition on pseudovirus infection at 10 uM incubated for 48 hrs by luciferase assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification, optimization, and biological evaluation of 3-O-β-chacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein. |
| AID1753197 | Selectivity index, ratio of IC50 for SARS-CoV-2 spike glycoprotein S inhibition to CC50 for cytotoxicity against human 293T/ACE2 cells | 2021 | European journal of medicinal chemistry, Apr-05, Volume: 215 | Discovery and structural optimization of 3-O-β-chacotriosyl oleanane-type triterpenoids as potent entry inhibitors of SARS-CoV-2 virus infections. |
| AID1859993 | Antiviral activity against pseudovirus SARS-CoV-2 spike protein infected human HEK293T cells overexpressing ACE2 assessed as inhibition on pseudovirus infection at 40 uM incubated for 48 hrs by luciferase assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification, optimization, and biological evaluation of 3-O-β-chacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein. |
| AID1424741 | Cytotoxicity against mouse RAW264.7 cells assessed as effect on cell viability at 1 to 10 uM after 24 hrs by MTT assay relative to control | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Design, synthesis and biological evaluation of novel xanthine oxidase inhibitors bearing a 2-arylbenzo[b]furan scaffold. |
| AID1753195 | Inhibition of spike glycoprotein S in SARS-CoV-2 pseudovirus infected human 293T/ACE2 cells assessed as inhibition of viral infection measured after 48 hrs by by luciferase reporter gene assay | 2021 | European journal of medicinal chemistry, Apr-05, Volume: 215 | Discovery and structural optimization of 3-O-β-chacotriosyl oleanane-type triterpenoids as potent entry inhibitors of SARS-CoV-2 virus infections. |
| AID1433310 | Antioxidant activity in LPS induced mouse RAW264.7 cells assessed as superoxide anion scavenging activity at 10 uM after 24 hrs by HE probe based HPLC-MS analysis relative to control | 2016 | European journal of medicinal chemistry, Nov-29, Volume: 124 | Synthesis and evaluation of xanthine oxidase inhibitory and antioxidant activities of 2-arylbenzo[b]furan derivatives based on salvianolic acid C. |
| AID1753196 | Cytotoxicity against human 293T/ACE2 cells measured after 48 hrs by MTT assay | 2021 | European journal of medicinal chemistry, Apr-05, Volume: 215 | Discovery and structural optimization of 3-O-β-chacotriosyl oleanane-type triterpenoids as potent entry inhibitors of SARS-CoV-2 virus infections. |
| AID1871462 | Displacement of [3H]2MeSADP from human P2Y12 expressed in U2OS cell membranes incubated for 60 mins by scintillation counting method | |||
| AID1433309 | Antioxidant activity assessed as DPPH radical scavenging activity incubated for 30 mins under dark conditions by spectrophotometry | 2016 | European journal of medicinal chemistry, Nov-29, Volume: 124 | Synthesis and evaluation of xanthine oxidase inhibitory and antioxidant activities of 2-arylbenzo[b]furan derivatives based on salvianolic acid C. |
| AID1433308 | Inhibition of Xanthine oxidase (unknown origin) using xanthine as substrate preincubated for 3 mins followed by substrate addition measured every 15 secs for 7 mins by spectrophotometry | 2016 | European journal of medicinal chemistry, Nov-29, Volume: 124 | Synthesis and evaluation of xanthine oxidase inhibitory and antioxidant activities of 2-arylbenzo[b]furan derivatives based on salvianolic acid C. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (65.38) | 24.3611 |
| 2020's | 9 (34.62) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.67) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 26 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||